We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA's Center for Biologics Evaluation and Research (CBER) plans this year to develop a template for reviewing proposed products, implement a formal training program for reviewers and create more opportunities for biotech firms and other stakeholders to provide input on efforts to enhance the development of new products.